A$236.05 -1.1 -0.4%
Last Trade - 24/01/20
| Market Cap | £7.11bn |
| Enterprise Value | £7.16bn |
| Revenue | £744.4m |
| Position in Universe | 39th / 1828 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Cochlear Limited is engaged in providing implantable hearing solutions. The Company's implant systems comprise an implant, which is inserted during surgery and an external sound processor. The Company operates through three segments, based on geographical basis: Americas, EMEA and Asia Pacific. Americas includes the United States, Canada and Latin America. EMEA includes Europe, Middle East and Africa. Asia Pacific includes Australasia and Asia. The Company's products and solutions include Cochlear implants, such as Nucleus 6 System and Aqua+; Bone conduction implants, such as Baha Attract and Baha Connect; Acoustic implant solutions, such as Cochlear Carina System, Cochlear MET System and Cochlear Codacs System, and Cochlear True Wireless range, such as Cochlear WIRELESS Mini Microphone 2, Cochlear Wireless Mini Microphone 2+, Cochlear Wireless Phone Clip and Cochlear Wireless TV Streamer. The Company sells its products in over 100 countries.
| Last Annual | June 30th, 2019 |
| Last Interim | June 30th, 2019 |
| Incorporated | June 8, 1983 |
| Public Since | December 4, 1995 |
| No. of Shareholders: | 34,046 |
| No. of Employees: | 4,000 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | S&P/ASX 50 , S&P/ASX All Ordinaries , S&P/ASX 100 , S&P/ASX 200 , S&P/ASX 300 , FTSE Developed Asia Pacific , FTSE Developed Asia Pacific Ex Japan , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 57,715,821 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1 University Avenue,Macquarie University, SYDNEY, 2109, Australia |
| Web | http://www.cochlear.com/ |
| Phone | +61 2 94286555 |
| Auditors | KPMG |
